Show Notes
In this episode of The GLP-1 Podcast Show, I speak with Dr. Jon Campbell, Associate Professor of Medicine at Duke University, about the changing science of GIP and glucagon. We examine GIP physiology, glucagon signaling, weight-independent metabolic effects, multi-receptor agonism, and variability in treatment response. Discover how emerging pharmacology could shape more precise obesity treatment. Listen now on all major platforms.
"GI think it’s going to take a little while, but people are going to come around to this idea that glucagon, particularly when combined with an incretin like GIP or GLP-1, is a really powerful way to improve metabolic disease."
Meet the guest: Dr. Jon Campbell is an Associate Professor of Medicine at Duke University. His research examines incretin hormones, pancreatic islet biology, and the cellular mechanisms that regulate glucose metabolism. His work has helped advance understanding of GIP, GLP-1, glucagon, and the signaling pathways that may shape future metabolic therapies. Listen to Dr. Jon Campbell on The GLP-1 Podcast Show, available on all major platforms.
What you will learn: (00:00) Highlight (01:02) Introduction (02:09) GIP biology (06:04) Hormone contributions (11:45) Optimized agonists (15:33) Glucagon actions (19:21) Multi-hormone therapies (25:46) Closing thoughts
The GLP-1 Podcast Show is trusted and supported by innovative companies like:
- Zentrix Insights (https://zentrixinsights.com/) - ZentrixOS (https://zentrixos.com/) - WiseVAs (https://www.wisevas.io/) - Elevate (https://elevateagents.ai/)
𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://theglp1podcast.com/ LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/ Instagram: https://www.instagram.com/theglp1podcast/ Facebook: https://www.facebook.com/profile.php?id=61577863745840 TikTok: https://www.tiktok.com/@theglp1podcast
More from The GLP-1 Podcast Show
In this episode of The GLP-1 Podcast Show, I speak with Dr. Anders Fink-Jensen, Professor of Psychiatry at the University of Copenhagen and a consultant psychiatrist, about the emerging role of GLP-1 receptor agonists in addiction treatment. We examine the clinical observations that initiated this research, findings from a randomized trial of semaglutide for alcohol use disorder, possible effects on craving, dosing considerations, and the evidence still needed before broader clinical use. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Michelle Gordon, a physician board-certified in obesity medicine and CEO of Thrive Span Medical, about obesity care for women in midlife. We discuss how GLP-1 therapy fits into long-term disease management, why slower weight reduction, adequate protein, resistance training, hydration, and fiber matter, and how hormonal changes may affect weight, cognition, and metabolic health. Dr. Gordon also explains when bariatric surgery remains appropriate and why obesity should be treated as a complex chronic disease. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Ashley Koff, registered dietitian, founder of The Better Nutrition Program, and bestselling author of Your Best Shot, about weight health in the GLP-1 era. She explains why body composition matters more than total weight, how digestion and hydration shape nutrition outcomes, why protein advice must be personalized, and how clinicians can support more sustainable metabolic health. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Timothy Garvey, Endowed Professor of Medicine at the University of Alabama at Birmingham, about complication-centric care for Adiposity-Based Chronic Disease. We examine current obesity guidelines, medication selection according to complications, what the key unmet clinical need is in obesity care, and the role of second-generation GLP-1 medications in type 2 diabetes. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Christopher Kramer, Chief of the Cardiovascular Division at the University of Virginia Health, about how GLP-1 and GIP therapies are reshaping the treatment of obesity-related heart failure. We explore cardiac remodeling, adipose tissue reduction, cardiovascular outcomes, and the mechanisms behind improved patient health. Listen now on all major platforms!